NRx Pharmaceuticals, Inc. Q2 2026 Earnings Recap

NRXP Q2 2026 August 19, 2026

Get alerts when NRXP reports next quarter

NRx Pharmaceuticals shares rose 5.2% following Q2 results, driven by significant progress toward regulatory approvals and a promising federally backed clinical trial partnership that expands the potential market for NRX-101.

Earnings Per Share Miss

$-0.44 vs $-0.11 est.

-312.5% surprise

Revenue Miss

1101000 vs 1329667 est.

-17.2% surprise

Market Reaction

Post-Earnings +5.20%

Aug 19 to Aug 26 +3.9%

See NRXP alongside your other holdings

Add to your portfolio — free

Key Takeaways

Completed first FDA review cycle for preservative-free ketamine ANDA with only one minor manufacturing-related deficiency remaining, targeting approval in 2026.
Advanced NRX-100 NDA with strong external alignment, supported by White House and Congressional guidance endorsing real-world evidence for psychedelic depression treatments; aiming for 2027 approval.
Secured a prime contractor role with DARPA for the SPARC-TMS trial of NRX-101 combined with robotic TMS, potentially opening a large new market in military and first responder mental health.
Expanded HOPE Therapeutics clinical footprint in Florida, supporting growth ambitions.
Ordered 5 million units of launch stock for preservative-free ketamine, reflecting confidence in upcoming commercial readiness.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit NRXP on AllInvestView.